Regeneron Pharmaceuticals Sued for Securities Law Violations

DJS Law Group has announced the filing of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN), alleging violations of federal securities laws. The lawsuit specifically cites alleged breaches of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

The complaint asserts that Regeneron made materially false and misleading statements to investors and failed to disclose material adverse facts about the company's business and prospects during the relevant class period. These allegations point to potential misrepresentations or omissions that could have impacted the stock's valuation.

Investors who purchased Regeneron securities during the specified class period and suffered losses are encouraged by DJS Law Group to contact the firm to discuss their rights and potential participation in the lawsuit. The class action aims to represent all individuals who were harmed by the alleged misconduct.

Further details regarding the lawsuit and the claims against Regeneron are available through DJS Law Group. Potential claimants are advised to seek legal counsel promptly.